Correction of Complications of Poly Cystic Ovary Syndrome by Alpha lipoic Acid in Undergoing ICSI Treatment Wome
Phase 3
Recruiting
- Conditions
- Poly Cystic Ovarian Syndrome.E28.2: Polycystic Ovarian SyndromeE28.2
- Registration Number
- IRCT20191210045681N1
- Lead Sponsor
- Iranian academic center for education culture and research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Periodic Disorders (Oligomenorrhea or Amenorrhea Patients). Hirsutism, Infertility
LH / FSH Ratio Increased
Ultrasound View of Ovary Size and Multiple Follicles 2-10 mm in Size
Normal Sperm Analysis
Normal Thyroid Function and Prolactin Levels
Natural Hystero Salpingography
No Endometriosis
Exclusion Criteria
Non-Ovulatory Infertility Factors
Male Factor Infertility
Pelvic Organ Damage
Congenital Adrenal Hyperplasia
Thyroid Dysfunction
Cushing's Syndrome
Severe or Renal Liver Diseases
Active Gastric Ulcer
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measurement of Biochemical Markers. Timepoint: Before and 8 Weeks after Drug Administration. Method of measurement: Elisa Kit.;Stress Oxidative Level. Timepoint: 8 Weeks. Method of measurement: Laboratory Kits.;Oocyte and Embryo Quality. Timepoint: 8 Weeks. Method of measurement: Shape and Morphology.
- Secondary Outcome Measures
Name Time Method Pregnancy Rate. Timepoint: 8 Weeks. Method of measurement: Laboratory Kits.